OMDA · Omada Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · OMDA
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q4 '22 |
|---|---|---|---|---|---|
| Revenue | $78.05M | - | $68.03M | $61.37M | - |
| Cost of Revenue | $29.36M | - | $22.96M | $16.38M | - |
| Gross Profit | $31.90M | - | $45.07M | $24.83M | - |
| R&D | $12.70M | - | $10.30M | $8.99M | - |
| SG&A | $13.99M | - | $14.34M | $12.31M | - |
| Total Operating Expenses | $40.30M | - | $37.09M | $44.65M | - |
| D&A | $1.33M | - | - | - | - |
| Operating Income | ($4.78M) | - | ($8.52M) | ($10.04M) | - |
| Interest Expense | $18.0K | - | $1.15M | $1.09M | - |
| Income Tax | $0 | - | $0 | $0 | - |
| Net Income | ($2.97M) | - | ($9.23M) | ($10.69M) | - |
| EPS - Basic | ($0.05) | - | ($0.06) | ($1.40) | - |
| EPS - Diluted | ($1.15) | - | ($0.06) | ($0.24) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q4 '22 |
|---|---|---|---|---|---|
| Cash & Equivalents | $211.76M | $222.04M | $198.63M | $76.39M | $168.12M |
| Accounts Receivable | $39.98M | $34.59M | $41.45M | $33.29M | - |
| Inventory | $3.83M | $4.49M | $3.15M | $3.30M | - |
| Accounts Payable | $8.10M | $10.28M | $5.34M | $7.40M | - |
| Current Assets | $269.43M | $272.93M | $254.90M | $113.06M | - |
| Total Assets | $302.80M | $305.41M | $287.47M | $302.97M | - |
| Current Liabilities | $68.68M | $75.73M | $70.12M | $57.99M | - |
| Long-term Debt | - | $0 | $0 | $29.77M | - |
| Total Liabilities | $68.68M | $75.73M | $70.12M | $86.26M | - |
| Stockholders' Equity | $234.12M | $229.68M | $217.35M | ($390.05M) | ($293.17M) |
| Retained Earnings | ($459.71M) | ($456.74M) | ($461.90M) | ($443.97M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q4 '22 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($16.12M) | - | - | - | - |
| Investing Cash Flow | ($1.25M) | - | - | - | - |
| Financing Cash Flow | $3.12M | - | - | - | - |
| CapEx | $315.0K | - | - | - | - |
| Free Cash Flow | ($16.43M) | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q4 '22 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 40.9% | - | 66.3% | 40.5% | - |
| Operating margin | -6.1% | - | -12.5% | -16.4% | - |
| EBITDA margin | -4.4% | - | - | - | - |
| Net margin | -3.8% | - | -13.6% | -17.4% | - |
| Free cash flow margin | -21.1% | - | - | - | - |
| FCF / Net income | 5.53 | - | - | - | - |
| R&D / Revenue | 16.3% | - | 15.1% | 14.6% | - |
| SG&A / Revenue | 17.9% | - | 21.1% | 20.1% | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -1.0% | - | -3.2% | -3.5% | - |
| Return on equity | -1.3% | - | -4.2% | 2.7% | - |
| Return on invested capital | - | - | -3.1% | - | - |
| Liquidity | |||||
| Current ratio | 3.92 | 3.60 | 3.64 | 1.95 | - |
| Quick ratio | 3.87 | 3.54 | 3.59 | 1.89 | - |
| Cash ratio | 3.08 | 2.93 | 2.83 | 1.32 | - |
| Leverage | |||||
| Debt / Equity | - | 0.00 | 0.00 | -0.08 | - |
| Debt / Assets | - | 0.00 | 0.00 | 0.10 | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -265.6x | - | -7.4x | -9.2x | - |
| Equity multiplier | 1.29 | 1.33 | 1.32 | -0.78 | - |
| Liabilities / Assets | 0.23 | 0.25 | 0.24 | 0.28 | - |
| Efficiency | |||||
| Asset turnover | 0.26 | - | 0.24 | 0.20 | - |
| Inventory turnover | 7.66 | - | 7.29 | 4.97 | - |
| Days sales outstanding | 187d | - | 222d | 198d | - |
| Days inventory outstanding | 48d | - | 50d | 73d | - |
| Days payable outstanding | 101d | - | 85d | 165d | - |
| Cash conversion cycle | 134d | - | 187d | 106d | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 3.2x | - | 5.9x | - | - |
| P / S | 9.5x | - | 18.7x | 2.3x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$260.21M totalReportable Segment$260.21M · 100.0%
Product / service
$260.21M totalService$241.04M · 92.6%
Hardware$19.17M · 7.4%
Peer comparison
Same SIC group: Services-Health Services
Comparing Omada Health against the 5 most active filers in the same SIC group.